Press Release

Submission of Clinical Trial Protocol Notice for Corneal Endothelial Therapy Cell Therapy, “AE101”

ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for “AE101,” a cutting-edge therapy for the treatment of bullous keratopathy, to the Pharmaceuticals and Medical Devices Agency (PMDA). After PMDA’s 30-day investigation of the clinical trial protocol, we anticipate commencing the clinical trial.


This website uses cookies for the purpose of operating our services and improving the user experience. For details, please refer to our privacy policy. By clicking on the “Agree” button or continuing to use our website, you will be regarded as having agreed to our use of cookies.